» Articles » PMID: 18651165

Long-term Experience on Surgical Treatment of Alveolar Echinococcosis

Overview
Specialty General Surgery
Date 2008 Jul 25
PMID 18651165
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Alveolar echinococcosis (AE) is life-threatening and reports on surgical procedures and results are rare, but essential.

Materials And Methods: Longitudinal surveillance and long-term follow-up of patients surgically treated for AE during the periods 1982-1999 (group A) and 2000-2006 (group B).

Setting: University hospital within an endemic area.

Results: The median (min-max) follow-up period was 141 (5-417) months. Forty-eight surgical procedures were performed in 36 patients with AE: 63% were partial resections of the liver (additional extrahepatic resection in ten of them), 17% just extrahepatic resections, 10% biliodigestive anastomosis, and 10% exploratory laparotomies. Seventy-five percent of the operations were first-time procedures, 25% done due to a relapse. Forty-two percent of the operations were estimated to be curative (R0), whereas 58% were palliative (R1, R2). All patients had additional medical treatment and periodical follow-up. Two out of 18 (11%) patients, estimated to have had curative surgery, developed a relapse 42 and 54 months later. R0-resection rates depended on the primary, neighboring, metastasis stage of AE (S1, 100%; S2, 100%; S3a, 33%; S3b, 27%; S4, 11%). During the period 2000-2006 elective radical surgery for AE was done only if a safe distance of at least 2 cm was attainable. This concept was associated with an increased R0-resection rate of 87% for group B compared to 24% for group A. Operative procedures done to control complicated courses of AE (jaundice, cholangitis, vascular compression, bacterial superinfection) have not been curative (R2) in 82% because the disease had spread into irresectable structures. Morbidity was 19%. All patients with curative resections are alive. Fifty-six percent of the patients with palliative treatment are alive as long as 14-237 months, 28% died from AE 164-338 months after diagnosis (late lethality), and 17% died due to others diseases 96-417 months after diagnosis of AE. One out of seven (14%) patients suffering from suppurative parasitic necrosis died because it was impossible to control systemic sepsis (3% hospital lethality).

Conclusion: Curative surgery for AE is feasible if the parasitic mass is removable entirely. The earlier the stage, the more frequent is R0 resectability. The observance of a minimal safe distance increases the rate of R0 resections. The benefit of palliative surgery is uncertain due to favorable long-term results of medical treatment alone. However, necrotic tissue is at risk of bacterial superinfection, which can cause life-threatening sepsis. Palliative surgery is an option to treat complications, which could not be managed otherwise.

Citing Articles

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.

Liu H, Xie Y, An X, Xu D, Cai S, Chu C Diagnostics (Basel). 2025; 15(5).

PMID: 40075832 PMC: 11898896. DOI: 10.3390/diagnostics15050585.


CT-based radiomics models using intralesional and different perilesional signatures in predicting the microvascular density of hepatic alveolar echinococcosis.

Hou J, Zhang S, Li S, Zhao Z, Zhao L, Zhang T BMC Med Imaging. 2025; 25(1):84.

PMID: 40065220 PMC: 11895365. DOI: 10.1186/s12880-025-01612-5.


Rare presentation of hepatic alveolar echinococcosis mimicking hepatocellular carcinoma.

Zanib A, Ahmed A, Salvia Milos A, Musavi S BMJ Case Rep. 2024; 17(9).

PMID: 39242125 PMC: 11409352. DOI: 10.1136/bcr-2024-259701.


Efficacy of percutaneous microwave ablation guided by contrast-enhanced and two-dimensional ultrasound for in hepatic alveolar echinococcosis in difficult/dangerous locations.

Huang W, Hu Z, Qi L, Zhang X, Li M, Yu M Front Med (Lausanne). 2024; 11:1436753.

PMID: 39185469 PMC: 11341408. DOI: 10.3389/fmed.2024.1436753.


Bacterial Infection of an Alveolar Echinococcus Cyst from Septicemia: A Case Report and Review of the Literature.

Buttenschoen J, Pavel V, Mehrl A, Michels B, Albaladejo Fuertes S, Seydel B Medicina (Kaunas). 2023; 59(10).

PMID: 37893546 PMC: 10608314. DOI: 10.3390/medicina59101828.


References
1.
Ammann R, Hoffmann A, Eckert J . [Swiss study of chemotherapy of alveolar echinococcosis--review of a 20-year clinical research project]. Schweiz Med Wochenschr. 1999; 129(8):323-32. View

2.
Reuter S, Nussle K, Kolokythas O, Haug U, Rieber A, Kern P . Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection. 2001; 29(3):119-25. DOI: 10.1007/s15010-001-1081-2. View

3.
. Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ. 1996; 74(3):231-42. PMC: 2486920. View

4.
Ammann R . Improvement of liver resectional therapy by adjuvant chemotherapy in alveolar hydatid disease. Swiss Echinococcosis Study Group (SESG). Parasitol Res. 1991; 77(4):290-3. DOI: 10.1007/BF00930903. View

5.
Craig P, Deshan L, Macpherson C, Dazhong S, Reynolds D, Barnish G . A large focus of alveolar echinococcosis in central China. Lancet. 1992; 340(8823):826-31. DOI: 10.1016/0140-6736(92)92693-a. View